

Fred Saad

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8610879/publications.pdf>

Version: 2024-02-01

752
papers

52,500
citations

4388

86
h-index

1715

213
g-index

757
all docs

757
docs citations

757
times ranked

30480
citing authors

#	ARTICLE	IF	CITATIONS
1	Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 708-717.	3.2	3
2	Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 74-79.	3.9	6
3	Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. <i>European Urology Focus</i> , 2022, 8, 182-190.	3.1	15
4	Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aNOMO Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2022, 8, 191-199.	3.1	8
5	Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. <i>European Urology Focus</i> , 2022, 8, 498-505.	3.1	17
6	Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 399-408.	3.1	29
7	Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. <i>European Urology Focus</i> , 2022, 8, 710-717.	3.1	12
8	Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 139-148.	3.9	28
9	Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. <i>European Urology Focus</i> , 2022, 8, 1133-1140.	3.1	11
10	The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 57.e15-57.e23.	1.6	7
11	Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 615-626.	3.9	27
12	The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. <i>World Journal of Urology</i> , 2022, 40, 103-110.	2.2	9
13	External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 17-24.	1.0	7
14	Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. <i>Cancer Causes and Control</i> , 2022, 33, 25-35.	1.8	4
15	Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. <i>Journal of Urology</i> , 2022, 207, 16-24.	0.4	31
16	Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. <i>European Urology Focus</i> , 2022, 8, 958-967.	3.1	9
17	Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 375-384.	0.4	18
18	The cardiovascular effects of gonadotropin-releasing hormone antagonists in men with prostate cancer. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 253-262.	3.0	21

#	ARTICLE	IF	CITATIONS
19	Improving the stratification of intermediate risk prostate cancer. <i>Minerva Urology and Nephrology</i> , 2022, 74, .	2.5	10
20	Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. <i>Prostate</i> , 2022, 82, 120-131.	2.3	2
21	Survival benefit of chemotherapy in a contemporary cohort of metastatic urachal carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 165.e9-165.e15.	1.6	8
22	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	2.4	4
23	Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. <i>Prostate</i> , 2022, 82, 78-85.	2.3	3
24	Contemporary Trends and Efficacy of Pelvic Lymph Node Dissection at Radical Cystectomy for Urothelial and Variant Histology Carcinoma of the Urinary Bladder. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 195.e1-195.e8.	1.9	3
25	Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. <i>International Journal of Urology</i> , 2022, 29, 96-96.	1.0	3
26	Immuno-oncology therapy in metastatic bladder cancer: A systematic review and network meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103534.	4.4	5
27	Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. <i>International Urology and Nephrology</i> , 2022, 54, 89-95.	1.4	2
28	Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. <i>European Journal of Cancer</i> , 2022, 160, 61-71.	2.8	29
29	Radiographic progression-free survival in the ACIS trial for prostate cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2022, 23, e5-e6.	10.7	1
30	Improving outcomes of men with incurable prostate cancer. <i>Lancet</i> , The, 2022, 399, 413-415.	13.7	0
31	Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. <i>Prostate International</i> , 2022, 10, 21-27.	2.3	3
32	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	2.4	10
33	Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. <i>World Journal of Urology</i> , 2022, 40, 1481-1488.	2.2	8
34	Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. <i>European Urology</i> , 2022, 81, 184-192.	1.9	12
35	Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2022, 23, 362-373.	10.7	97
36	Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. <i>Journal of Bone Oncology</i> , 2022, 33, 100416.	2.4	21

#	ARTICLE	IF	CITATIONS
37	Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases, 2022, 25, 86-92.	3.9	23
38	Survival after radical prostatectomy versusÂradiation therapy in clinical nodeâ€positive prostate cancer. Prostate, 2022, 82, 740-750.	2.3	7
39	Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. Prostate, 2022, 82, 676-686.	2.3	4
40	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer and Prostatic Diseases, 2022, 25, 306-313.	3.9	5
41	PSMAddition: A phase 3 trial to compare treatment with ¹⁷⁷Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer.. Journal of Clinical Oncology, 2022, 40, TPS210-TPS210.	1.6	16
42	Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. Cancers, 2022, 14, 1222.	3.7	7
43	Nonâ€organ confined stage and upgrading rates in exclusive PSA highâ€risk prostate cancer patients. Prostate, 2022, 82, 687-694.	2.3	3
44	PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. BMC Cancer, 2022, 22, 251.	2.6	5
45	Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 2022, 386, 1132-1142.	27.0	341
46	Pre-activation of autophagy impacts response to olaparib in prostate cancer cells. Communications Biology, 2022, 5, 251.	4.4	6
47	Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes and Control, 2022, 33, 769-777.	1.8	1
48	Grade and stage misclassification in intermediate unfavorableâ€risk prostate cancer radiotherapy candidates. Prostate, 2022, , .	2.3	4
49	Emerging treatment options for bacillus Calmetteâ€GuÃ©rin-unresponsive non-muscle invasive bladder cancer. Current Opinion in Supportive and Palliative Care, 2022, 16, 48-53.	1.3	2
50	Targeting IKKÎµ in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability. Molecular Cancer Therapeutics, 2022, 21, 407-418.	4.1	2
51	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers, 2022, 14, 1623.	3.7	5
52	Contemporary seminal vesicle invasion rates in NCCN highâ€risk prostate cancer patients. Prostate, 2022, 82, 1051-1059.	2.3	6
53	Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers?. Journal of Clinical Oncology, 2022, 40, 3011-3014.	1.6	12
54	Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology, 2022, 82, 115-141.	1.9	51

#	ARTICLE	IF	CITATIONS
55	Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 380.e19-380.e27.	1.6	7
56	Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology, 2022, 82, 82-96.	1.9	15
57	Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. Journal of Medical Economics, 2022, 25, 583-590.	2.1	2
58	Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. International Urology and Nephrology, 2022, 54, 1521-1527.	1.4	10
59	Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer, 2022, 170, 296-304.	2.8	14
60	Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. Surgical Oncology, 2022, 42, 101783.	1.6	2
61	Patterns of care for nonâ€metastatic castrationâ€resistant prostate cancer: A populationâ€based study. BJUI Compass, 2022, 3, 383-391.	1.3	3
62	Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. Prostate, 2022, 82, 1210-1218.	2.3	2
63	Outcomes of roboticâ€assisted versus open radical cystectomy in a largeâ€scale, contemporary cohort of bladder cancer patients. Journal of Surgical Oncology, 2022, 126, 830-837.	1.7	7
64	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
65	High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients. Cancers, 2022, 14, 2790.	3.7	3
66	Addition of Docetaxel to Androgen Receptor Axisâ€targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. European Urology Oncology, 2022, 5, 494-502.	5.4	21
67	Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stagesâ€A SEER-based Study. European Urology Focus, 2021, 7, 1332-1338.	3.1	8
68	Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. European Urology Oncology, 2021, 4, 792-801.	5.4	40
69	Differences between rural and urban prostate cancer patients. World Journal of Urology, 2021, 39, 2507-2514.	2.2	12
70	Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Databaseâ€based Study. European Urology Focus, 2021, 7, 818-826.	3.1	7
71	Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World Journal of Urology, 2021, 39, 461-472.	2.2	15
72	Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. European Journal of Surgical Oncology, 2021, 47, 463-469.	1.0	7

#	ARTICLE	IF	CITATIONS
73	Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. World Journal of Urology, 2021, 39, 813-822.	2.2	6
74	PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World Journal of Urology, 2021, 39, 787-796.	2.2	10
75	Obesity is associated with adverse short-term perioperative outcomes in patients treated with open and robot-assisted radical cystectomy for bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 75.e17-75.e25.	1.6	7
76	Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Clinical Genitourinary Cancer, 2021, 19, 60-68.e1.	1.9	27
77	The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 236.e1-236.e7.	1.6	10
78	Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat?. Journal of Clinical Oncology, 2021, 39, 13-16.	1.6	9
79	External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 131.e1-131.e7.	1.6	2
80	Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas. Cancer Causes and Control, 2021, 32, 119-126.	1.8	1
81	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. Surgical Oncology, 2021, 36, 131-137.	1.6	4
82	The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 369.e9-369.e17.	1.6	4
83	Bladder cancer stage and mortality: urban vs. rural residency. Cancer Causes and Control, 2021, 32, 139-145.	1.8	10
84	External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer and Prostatic Diseases, 2021, 24, 253-260.	3.9	6
85	Apalutamide and Overall Survival in Prostate Cancer. European Urology, 2021, 79, 150-158.	1.9	150
86	Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592199858.	3.2	7
87	Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. JNCI Cancer Spectrum, 2021, 5, pkab082.	2.9	17
88	Sex- and age-related differences in the distribution of bladder cancer metastases. Japanese Journal of Clinical Oncology, 2021, 51, 976-983.	1.3	11
89	Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2021, 39, 101-101.	1.6	3
90	Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).. Journal of Clinical Oncology, 2021, 39, 94-94.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 323-334.	3.9	35
92	Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. <i>Journal of Clinical Pathology</i> , 2021, , jclinpath-2021-207400.	2.0	5
93	Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 25-37.	2.3	19
94	The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. <i>Prostate</i> , 2021, 81, 339-346.	2.3	13
95	Incidence rates and contemporary trends in primary urethral cancer. <i>Cancer Causes and Control</i> , 2021, 32, 627-634.	1.8	15
96	Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer. <i>Cancers</i> , 2021, 13, 1273.	3.7	4
97	Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. <i>Urologia Internationalis</i> , 2021, 105, 624-630.	1.3	6
98	Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality. <i>Cancers</i> , 2021, 13, 1688.	3.7	5
99	Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. <i>British Journal of Cancer</i> , 2021, 125, 78-84.	6.4	5
100	The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy. <i>Andrologia</i> , 2021, 53, e14070.	2.1	1
101	Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 135-143.	1.9	7
102	Do We Really Need Another Oncology Journal?. <i>Onco</i> , 2021, 1, 23-24.	0.6	0
103	Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 239.e1-239.e7.	1.6	5
104	Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 117-124.	1.9	22
105	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. <i>European Urology Focus</i> , 2021, 7, 598-607.	3.1	10
106	Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. <i>Prostate</i> , 2021, 81, 728-735.	2.3	11
107	The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 785.e11-785.e17.	1.6	6
108	Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. <i>World Journal of Urology</i> , 2021, 39, 3781-3787.	2.2	9

#	ARTICLE	IF	CITATIONS
109	Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. International Journal of Urology, 2021, 28, 834-839.	1.0	5
110	Presence of biopsy Gleason pattern 5+3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns+. Prostate, 2021, 81, 778-784.	2.3	2
111	Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. International Journal of Urology, 2021, 28, 862-869.	1.0	22
112	Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.. Journal of Clinical Oncology, 2021, 39, 5002-5002.	1.6	22
113	Treatment and trials in non-metastatic castration-resistant prostate cancer. Nature Reviews Urology, 2021, 18, 433-442.	3.8	32
114	Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology, 2021, 39, 4127-4133.	2.2	3
115	Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. European Urology Focus, 2021, 7, 644-652.	3.1	28
116	Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. International Journal of Clinical Oncology, 2021, 26, 1707-1713.	2.2	5
117	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	1.6	2
118	Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 789.e9-789.e17.	1.6	5
119	Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). European Urology Open Science, 2021, 28, 52-61.	0.4	9
120	Canadian consensus forum of key controversial areas in the management of advanced prostate cancer. Canadian Urological Association Journal, 2021, 15, 353-358.	0.6	2
121	A drug safety evaluation of enzalutamide to treat advanced prostate cancer. Expert Opinion on Drug Safety, 2021, 20, 741-749.	2.4	3
122	Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. Prostate, 2021, 81, 874-881.	2.3	15
123	Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. Cancers, 2021, 13, 2844.	3.7	10
124	Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer. JAMA Network Open, 2021, 4, e2112426.	5.9	2
125	Reply by Authors. Journal of Urology, 2021, 206, 79-79.	0.4	0
126	Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. Prostate, 2021, 81, 1055-1063.	2.3	2

#	ARTICLE	IF	CITATIONS
127	The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 788.e7-788.e13.	1.6	6
128	Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. JAMA Oncology, 2021, 7, 1005.	7.1	21
129	Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. Journal of Urology, 2021, 206, 69-79.	0.4	12
130	Radical Cystectomy vs. Multimodality Treatment in T2N0M0 Bladder Cancer: A Population-based, Age-matched Analysis. Clinical Genitourinary Cancer, 2021, 19, e264-e271.	1.9	9
131	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology, 2021, 4, 543-552.	5.4	11
132	The effect of primary urological cancers on survival in men with secondary prostate cancer. Prostate, 2021, 81, 1149-1158.	2.3	5
133	Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. Clinical Genitourinary Cancer, 2021, 19, e255-e263.	1.9	8
134	Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. European Journal of Cancer, 2021, 155, 245-255.	2.8	2
135	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncology, The, 2021, 22, 1250-1264.	10.7	159
136	Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. Surgical Oncology, 2021, 38, 101588.	1.6	8
137	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncology, The, 2021, 22, 1541-1559.	10.7	60
138	Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. Prostate, 2021, 81, 1374-1381.	2.3	8
139	Increased risk of postoperative in-hospital complications after radical prostatectomy in patients with prior organ transplant. Prostate, 2021, 81, 1294-1302.	2.3	0
140	Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. International Journal of Urology, 2021, 28, 1247-1252.	1.0	3
141	Radical cystectomy vs radiotherapy in urothelial bladder cancer in elderly and very elderly patients. Clinical Genitourinary Cancer, 2021, , .	1.9	2
142	Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases, 2021, , .	3.9	2
143	Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. Cancer Epidemiology, 2021, 74, 101994.	1.9	8
144	The impact of sex and age on distribution of metastases in patients with renal cell carcinoma. International Journal of Clinical Oncology, 2021, 26, 962-970.	2.2	4

#	ARTICLE	IF	CITATIONS
145	Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 74.e1-74.e7.	1.6	4
146	Canadian Urologic Association best practice report: Bone health in prostate cancer. Canadian Urological Association Journal, 2021, 15, 375-382.	0.6	3
147	Editorial: Patient selection in urologic oncology - one size does not fit all. Current Opinion in Supportive and Palliative Care, 2021, 15, 239-240.	1.3	0
148	The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. Frontiers in Oncology, 2021, 11, 754996.	2.8	0
149	Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics, 2021, 26, .	2.6	4
150	The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers, 2021, 13, 5872.	3.7	3
151	Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 778858.	2.8	7
152	Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. International Urology and Nephrology, 2021, 54, 81.	1.4	1
153	Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers, 2021, 13, 5830.	3.7	19
154	Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer, 2021, 159, 237-246.	2.8	6
155	Sex- and Age-Related Differences in the Distribution of Metastases in Patients With Upper Urinary Tract Urothelial Carcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 534-540.	4.9	7
156	UPDATE “ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Canadian Urological Association Journal, 2021, 16, E184-96.	0.6	12
157	UPDATE “ 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis: Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging “ Summary of changes. Canadian Urological Association Journal, 2021, 16, 86-87.	0.6	1
158	Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients. Frontiers in Oncology, 2021, 11, 780507.	2.8	3
159	Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers, 2021, 13, 6243.	3.7	1
160	Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. European Urology Focus, 2020, 6, 1213-1219.	3.1	5
161	External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. International Urology and Nephrology, 2020, 52, 59-66.	1.4	4
162	Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. European Urology Oncology, 2020, 3, 631-639.	5.4	4

#	ARTICLE	IF	CITATIONS
163	Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 129-137.e3.	1.9	11
164	Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. <i>Journal of Geriatric Oncology</i> , 2020, 11, 718-723.	1.0	21
165	Conditional survival of patients with stage Iâ€“III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. <i>World Journal of Urology</i> , 2020, 38, 725-732.	2.2	10
166	Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. <i>World Journal of Urology</i> , 2020, 38, 1535-1544.	2.2	8
167	Prostate cancer characteristics and cancer-specific mortality of Native American patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 277-285.	3.9	6
168	Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 260-268.	3.9	5
169	Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. <i>Surgical Oncology</i> , 2020, 32, 8-13.	1.6	39
170	Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 35-44.e1.	1.9	2
171	Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 79.e9-79.e14.	1.6	18
172	Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 284-294.	1.9	91
173	A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 314-321.e1.	1.9	11
174	Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 83-93.	1.6	24
175	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e450-e456.	1.9	5
176	Primary lymphomas of the genitourinary tract: A population-based study. <i>Asian Journal of Urology</i> , 2020, 7, 332-339.	1.2	3
177	Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 76.e1-76.e9.	1.6	22
178	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. <i>Clinical Genitourinary Cancer</i> , 2020, 18, 117-128.e5.	1.9	6
179	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
180	Can Exercise Adaptations Be Maintained in Men with Prostate Cancer Following Supervised Programmes? Implications to the COVID-19 Landscape of Urology and Clinical Exercise. <i>European Urology Open Science</i> , 2020, 21, 47-50.	0.4	7

#	ARTICLE	IF	CITATIONS
181	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. <i>European Urology</i> , 2020, 78, 847-853.	1.9	9
182	Active surveillance before radiotherapy – outcome and predictive factors for multiple biopsies before treatment. <i>Canadian Urological Association Journal</i> , 2020, 15, E36-E40.	0.6	0
183	Comparing Perspectives of Canadian Men Diagnosed With Prostate Cancer and Health Care Professionals About Active Surveillance. <i>Journal of Patient Experience</i> , 2020, 7, 1122-1129.	0.9	3
184	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 567-574.	1.3	3
185	A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. <i>Radiotherapy and Oncology</i> , 2020, 152, 80-88.	0.6	9
186	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
187	Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. <i>Canadian Urological Association Journal</i> , 2020, 15, E90-E96.	0.6	3
188	Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. <i>PLoS Medicine</i> , 2020, 17, e1003281.	8.4	19
189	PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence. <i>Cancers</i> , 2020, 12, 3187.	3.7	4
190	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	7.0	11
191	Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e730-e738.	1.9	9
192	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 680-688.	3.9	20
193	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2197-2206.	27.0	253
194	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2187-2196.	27.0	259
195	Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. <i>European Urology</i> , 2020, 78, 347-357.	1.9	75
196	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. <i>Urology</i> , 2020, 140, 91-97.	1.0	2
197	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 506-514.	1.6	4
198	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>Journal of Endourology</i> , 2020, 34, 600-607.	2.1	6

#	ARTICLE	IF	CITATIONS
199	Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 573-580.	3.9	22
200	Adherence to guideline recommendations for multimodality treatment of patients with pT2â€³ MO nonâ€urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. <i>International Journal of Urology</i> , 2020, 27, 402-407.	1.0	1
201	Risk Stratification of Prostate Cancer Through Quantitative Assessment of PTEN Loss (qPTEN). <i>Journal of the National Cancer Institute</i> , 2020, 112, 1098-1104.	6.3	21
202	The relationship between preâ€radiation therapy testosterone levels and prostate cancer aggressiveness. <i>Andrologia</i> , 2020, 52, e13731.	2.1	1
203	Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. <i>Cancer Epidemiology</i> , 2020, 67, 101762.	1.9	14
204	Contemporary conditional cancerâ€specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. <i>Journal of Surgical Oncology</i> , 2020, 121, 1154-1161.	1.7	20
205	The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. <i>Cancer Causes and Control</i> , 2020, 31, 283-290.	1.8	9
206	Small adrenal incidentaloma becoming an aggressive adrenocortical carcinoma in a patient carrying a germline APC variant. <i>Endocrine</i> , 2020, 68, 203-209.	2.3	4
207	Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 537-544.	1.6	13
208	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
209	Preoperative frailty predicts adverse shortâ€term postoperative outcomes in patients treated with radical nephroureterectomy. <i>Journal of Surgical Oncology</i> , 2020, 121, 688-696.	1.7	19
210	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. <i>Cancer Causes and Control</i> , 2020, 31, 263-272.	1.8	9
211	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
212	Pre-clinical evaluation of an image-guided in-situ Raman spectroscopy navigation system for targeted prostate cancer interventions. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2020, 15, 867-876.	2.8	5
213	Rates of otherâ€cause mortality after radical cystectomy are decreasing over timeâ€A populationâ€based analysis over two decades. <i>Journal of Surgical Oncology</i> , 2020, 121, 1329-1336.	1.7	5
214	Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1347-1352.	1.0	8
215	The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. <i>European Urology</i> , 2020, 78, 184-192.	1.9	46
216	Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. <i>European Urology</i> , 2020, 78, 603-614.	1.9	30

#	ARTICLE	IF	CITATIONS
217	Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e610-e618.	1.9	10
218	UPDATE “ 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019?. <i>Canadian Urological Association Journal</i> , 2020, 15, 11-2.	0.6	4
219	2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC) (full-text). <i>Canadian Urological Association Journal</i> , 2020, 15, E81-9.	0.6	10
220	Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. <i>Canadian Urological Association Journal</i> , 2020, 15, E307-E322.	0.6	10
221	Comparison Between Urothelial and Non-Urothelial Urethral Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 629692.	2.8	8
222	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. <i>World Journal of Urology</i> , 2020, 38, 2819-2826.	2.2	10
223	Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2020, 78, 834-844.	1.9	47
224	Renal Cell Carcinoma: Comparison between Variant Histology and Clear Cell Carcinoma across All Stages and Treatment Modalities. <i>Journal of Urology</i> , 2020, 204, 671-676.	0.4	17
225	The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 962-968.	0.4	11
226	Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5515-5515.	1.6	17
227	Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5516-5516.	1.6	41
228	Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5542-5542.	1.6	2
229	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRM) and metastatic castration-resistant prostate cancer (mCRPC) “ updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5566-5566.	1.6	15
230	Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience.. <i>Journal of Clinical Oncology</i> , 2020, 38, 195-195.	1.6	11
231	Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 32-32.	1.6	2
232	Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 44-51.	4.9	14
233	Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1492-1499.	4.9	8
234	Wide-field optical spectroscopy system integrating reflectance and spatial frequency domain imaging to measure attenuation-corrected intrinsic tissue fluorescence in radical prostatectomy specimens. <i>Biomedical Optics Express</i> , 2020, 11, 2052.	2.9	4

#	ARTICLE	IF	CITATIONS
235	Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Central European Journal of Urology, 2020, 73, 407-415.	0.3	3
236	Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2020, 38, 50-50.	1.6	0
237	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 880-888.	1.3	5
238	Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1340-1347.	4.9	6
239	Validation of the Social Security Administration Life Tables (2004â€“2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. European Urology Focus, 2019, 5, 807-814.	3.1	22
240	The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. World Journal of Urology, 2019, 37, 789-798.	2.2	7
241	Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. BJU International, 2019, 123, 624-631.	2.5	16
242	A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, 395-401.	1.9	9
243	Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. Anticancer Research, 2019, 39, 4357-4361.	1.1	17
244	Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. Clinical Genitourinary Cancer, 2019, 17, e1026-e1035.	1.9	19
245	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 578.e11-578.e19.	1.6	9
246	How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 893-899.	1.6	14
247	Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample. Urology, 2019, 133, 135-144.	1.0	18
248	Continuing to improve outcomes of men with metastatic prostate cancer. Nature Reviews Clinical Oncology, 2019, 16, 597-598.	27.6	2
249	Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e939-e945.	1.9	9
250	2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guidelines for the management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal, 2019, 13, 307-314.	0.6	21
251	Validation of the prognostic value of NF-ÎB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. PLoS Medicine, 2019, 16, e1002847.	8.4	23
252	Comprehensive analysis of in-hospital delirium after major surgical oncology procedures. Canadian Urological Association Journal, 2019, 14, E84-E93.	0.6	5

#	ARTICLE	IF	CITATIONS
253	Androgen Receptor Modulation Optimized for Responseâ€”Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7â€“expressing Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 76, 843-851.	1.9	36
254	A A Canadian consensus forum on the management of patients with advanced prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 14, E137-E149.	0.6	15
255	Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e1153-e1162.	1.9	8
256	The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. <i>Journal of Surgical Oncology</i> , 2019, 120, 1266-1275.	1.7	6
257	Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. <i>International Urology and Nephrology</i> , 2019, 51, 2181-2188.	1.4	12
258	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 7448-7454.	7.0	190
259	The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. <i>European Urology Oncology</i> , 2019, 2, 541-548.	5.4	31
260	Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of <i>ex vivo</i> solid tumors. <i>Lab on A Chip</i> , 2019, 19, 693-705.	6.0	14
261	Quality of life in men with prostate cancer. <i>Lancet Oncology</i> , The, 2019, 20, 325-326.	10.7	6
262	Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program. <i>BMC Cancer</i> , 2019, 19, 12.	2.6	36
263	Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based analysis. <i>Surgical Oncology</i> , 2019, 28, 201-207.	1.6	18
264	Pharmacodynamic and Clinical Results from a Phase I/II Study of the HSP90 Inhibitor Onalespib in Combination with Abiraterone Acetate in Prostate Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 4624-4633.	7.0	21
265	CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. <i>American Journal of Pathology</i> , 2019, 189, 1451-1461.	3.8	9
266	Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 696-701.	1.6	1
267	Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 348-355.e5.	1.9	27
268	Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. <i>BJU International</i> , 2019, 124, 1006-1013.	2.5	16
269	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e793-e801.	1.9	5
270	Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 702-710.	1.6	10

#	ARTICLE	IF	CITATIONS
271	Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 231-237.e2.	1.9	21
272	The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 623-631.	1.0	14
273	Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. <i>Journal of Endourology</i> , 2019, 33, 606-613.	2.1	12
274	Management algorithms for metastatic prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 50-60.	0.6	6
275	Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. <i>Radiation Oncology</i> , 2019, 14, 60.	2.7	18
276	Emerging therapeutic targets for patients with advanced prostate cancer. <i>Cancer Treatment Reviews</i> , 2019, 76, 1-9.	7.7	26
277	Importance of early treatment in metastatic prostate cancer: a question of life or death. <i>Lancet Oncology</i> , The, 2019, 20, 609-611.	10.7	1
278	WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. <i>Oncotmunology</i> , 2019, 8, e1581545.	4.6	28
279	Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e602-e611.	1.9	17
280	Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. <i>Journal of Endourology</i> , 2019, 33, 438-447.	2.1	41
281	Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 408-419.	10.7	276
282	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 701-706.	2.5	13
283	Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2019, 13, 420-426.	0.6	9
284	Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. <i>Cancer Epidemiology</i> , 2019, 59, 135-142.	1.9	9
285	Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1253-1259.	1.0	6
286	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	10.7	90
287	Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada. <i>Psycho-Oncology</i> , 2019, 28, 839-846.	2.3	2
288	Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. <i>International Journal of Urology</i> , 2019, 26, 487-492.	1.0	11

#	ARTICLE	IF	CITATIONS
289	Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naïve and castration-sensitive prostate cancer. Canadian Urological Association Journal, 2019, 14, 17-23.	0.6	17
290	Continuing towards optimization of bladder cancer care in Canada: Summary of the 3rd BCC-CUA-CUOG bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2019, 14, E115-E125.	0.6	3
291	Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study. Targeted Oncology, 2019, 14, 681-688.	3.6	6
292	Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Canadian Urological Association Journal, 2019, 14, E173-E179.	0.6	1
293	Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. European Journal of Surgical Oncology, 2019, 45, 1238-1245.	1.0	21
294	More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer, 2019, 17, 105-113.e2.	1.9	15
295	Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e130-e139.	1.9	23
296	Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. World Journal of Urology, 2019, 37, 1305-1313.	2.2	13
297	Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis?. Cancer Epidemiology, 2019, 58, 83-88.	1.9	15
298	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY. Clinical Cancer Research, 2019, 25, 1880-1888.	7.0	92
299	Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. World Journal of Urology, 2019, 37, 1329-1337.	2.2	4
300	Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. Clinical Genitourinary Cancer, 2019, 17, 72-78.e4.	1.9	10
301	Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology, 2019, 75, 44-60.	1.9	48
302	Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus, 2019, 5, 381-388.	3.1	12
303	The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus, 2019, 5, 399-406.	3.1	19
304	A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology and Oncology Research, 2019, 25, 979-986.	1.9	4
305	A Head-to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. European Urology Focus, 2019, 5, 449-456.	3.1	11
306	Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. Journal of Urology, 2019, 202, 1120-1126.	0.4	23

#	ARTICLE	IF	CITATIONS
307	Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study.. Journal of Clinical Oncology, 2019, 37, 5044-5044.	1.6	3
308	PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2019, 37, TPS340-TPS340.	1.6	10
309	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	1.9	6
310	V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. Oncotarget, 2019, 10, 4923-4936.	1.8	12
311	Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 445-456.	3.9	8
312	Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1344-1352.	4.9	8
313	SUN-373 Small Adrenal Incidentaloma Stable in Size Becoming a Stage IV Adrenocortical Carcinoma 10 Years Later in a Young Patient Carrying a Germline APC Variant of Uncertain Significance (VUS). Journal of the Endocrine Society, 2019, 3, .	0.2	0
314	Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. Prostate, 2018, 78, 469-475.	2.3	40
315	Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncolmunology, 2018, 7, e1445459.	4.6	26
316	The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. Prostate, 2018, 78, 697-706.	2.3	25
317	External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 239.e9-239.e15.	1.6	6
318	Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≥50 years: a population-based study. Prostate Cancer and Prostatic Diseases, 2018, 21, 71-77.	3.9	13
319	Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New England Journal of Medicine, 2018, 378, 1408-1418.	27.0	947
320	Simplified and robust one-step radiosynthesis of [¹⁸ F]DCFPyL via direct radiofluorination and cartridge-based purification. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 757-763.	1.0	11
321	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World Journal of Urology, 2018, 36, 1399-1407.	2.2	16
322	The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer Treatment Reviews, 2018, 68, 25-37.	7.7	37
323	A Phase II, Randomized, Multicenter Study Comparing 10 Months versus 4 Months of Degarelix Therapy in Prolonging the Off Treatment Interval in Men with Localized Prostate Cancer Receiving Intermittent Androgen Deprivation Therapy for Biochemical Recurrence following Radical Local Therapy. Journal of Urology, 2018, 200, 335-343.	0.4	9
324	Mesoscopic characterization of prostate cancer using Raman spectroscopy: potential for diagnostics and therapeutics. BJU International, 2018, 122, 326-336.	2.5	49

#	ARTICLE	IF	CITATIONS
325	Curative Treatment for Muscle Invasive Bladder Cancer in Elderly Patients: A Systematic Review. European Urology, 2018, 73, 40-50.	1.9	107
326	Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. European Urology Focus, 2018, 4, 834-841.	3.1	7
327	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. European Urology, 2018, 73, 178-211.	1.9	488
328	Does surgical delay for radical prostatectomy affect biochemical recurrence? A retrospective analysis from a Canadian cohort. World Journal of Urology, 2018, 36, 1-6.	2.2	20
329	Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology, 2018, 36, 7-13.	2.2	23
330	First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. BJU International, 2018, 121, 592-599.	2.5	32
331	Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology, 2018, 50, 71-78.	1.4	37
332	Canadian urology â€“ so much to be proud of. Canadian Urological Association Journal, 2018, 13, 153.	0.6	0
333	Reply to C. Ren et al. Journal of Clinical Oncology, 2018, 36, 2354-2356.	1.6	0
334	Ã€ tous les urologues canadiens, bienvenue Ã QuÃ©bec pour le congrÃ©s annuel 2019!. Canadian Urological Association Journal, 2018, 13, E30.	0.6	0
335	Welcome all Canadian urologists to Quebec City for CUA 2019!. Canadian Urological Association Journal, 2018, 13, 13.	0.6	0
336	Tout le poids dâ€™un nom, ou faut-il renommer notre spÃ©cialitÃ©?. Canadian Urological Association Journal, 2018, 12, E428.	0.6	0
337	Quâ€™est-ce que lâ€™urologie?. Canadian Urological Association Journal, 2018, 12, E364.	0.6	0
338	CUA â€“ Listening and learning how to best serve the urology community!. Canadian Urological Association Journal, 2018, 13, 81.	0.6	0
339	Ã‰couter et apprendre comment mieux servir les urologues. Canadian Urological Association Journal, 2018, 13, E104.	0.6	0
340	Lâ€™urologie au Canada â€“ de nombreuses raisons dâ€™Ãªtre fiers. Canadian Urological Association Journal, 2018, 13, 215.	0.6	0
341	Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. European Urology Oncology, 2018, 1, 169-175.	5.4	16
342	The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. European Urology Oncology, 2018, 1, 215-222.	5.4	12

#	ARTICLE	IF	CITATIONS
343	Improving outcome in patients with prostate and kidney cancer: heading in the right direction?. Current Opinion in Supportive and Palliative Care, 2018, 12, 323-324.	1.3	0
344	Management of nonmetastatic castration-resistant prostate cancer. Current Opinion in Supportive and Palliative Care, 2018, 12, 366-371.	1.3	1
345	North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. British Journal of Cancer, 2018, 119, 1552-1556.	6.4	10
346	Impact of adipose tissue on prostate cancer aggressiveness â€” analysis of a high-risk population. Hormone Molecular Biology and Clinical Investigation, 2018, 36, .	0.7	8
347	Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Canadian Urological Association Journal, 2018, 12, 328-336.	0.6	6
348	Canadian Urological Association Best Practice Report: Diagnosis and management of radiation-induced hemorrhagic cystitis. Canadian Urological Association Journal, 2018, 13, 15-23.	0.6	13
349	The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. BMC Urology, 2018, 18, 78.	1.4	14
350	Targeted Alpha Therapy, an Emerging Class of Cancer Agents. JAMA Oncology, 2018, 4, 1765.	7.1	143
351	Enzalutamide in Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2018, 379, 1380-1381.	27.0	10
352	What is urology?. Canadian Urological Association Journal, 2018, 12, 225.	0.6	0
353	Whatâ€™s in a name? Renaming our specialty?. Canadian Urological Association Journal, 2018, 12, 298.	0.6	0
354	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers, 2018, 10, 379.	3.7	21
355	The effect of race on survival after local therapy in metastatic prostate cancer patients. Canadian Urological Association Journal, 2018, 13, 175-181.	0.6	2
356	Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Journal of Cancer, 2018, 103, 78-87.	2.8	71
357	Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2018, 19, 1404-1416.	10.7	105
358	Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiology, 2018, 56, 118-125.	1.9	19
359	Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. International Journal of Urology, 2018, 25, 929-936.	1.0	3
360	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. BMJ Open, 2018, 8, e022899.	1.9	85

#	ARTICLE	IF	CITATIONS
361	Reliably Quantifying Bone Metastases in Prostate Cancer—Are We Finally There?. JAMA Oncology, 2018, 4, 951.	7.1	1
362	Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology, 2018, 1, 314-320.	5.4	19
363	Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. Canadian Urological Association Journal, 2018, 12, E365-E372.	0.6	7
364	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. New England Journal of Medicine, 2018, 378, 2465-2474.	27.0	782
365	Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma. Canadian Urological Association Journal, 2018, 12, 243-251.	0.6	10
366	Landmarks in prostate cancer. Nature Reviews Urology, 2018, 15, 627-642.	3.8	78
367	Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. BMC Health Services Research, 2018, 18, 430.	2.2	10
368	Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology, 2018, 36, 572-580.	1.6	187
369	Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. Canadian Urological Association Journal, 2018, 12, E415-20.	0.6	2
370	Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology, 2018, 74, 693-696.	1.9	19
371	Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology, 2018, 1, 160-168.	5.4	15
372	An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology, 2018, 82, 457-468.	2.3	18
373	Improving patient journey and quality of care: Summary from the second Bladder Cancer Canada-Canadian Urological Association- Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal, 2018, 12, E281-97.	0.6	9
374	In-hospital length of stay after major surgical oncological procedures. European Journal of Surgical Oncology, 2018, 44, 969-974.	1.0	34
375	Treatment of hormone-naïve metastatic prostate cancer. Current Opinion in Supportive and Palliative Care, 2018, 12, 334-338.	1.3	3
376	Combining high wavenumber and fingerprint Raman spectroscopy for the detection of prostate cancer during radical prostatectomy. Biomedical Optics Express, 2018, 9, 4294.	2.9	39
377	Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncology, The, 2018, 19, 975-986.	10.7	296
378	Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 365.e1-365.e7.	1.6	9

#	ARTICLE	IF	CITATIONS
379	SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology, 2018, 36, 161-161.	1.6	8
380	Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database. Canadian Journal of Urology, 2018, 25, 9509-9515.	0.0	8
381	Modeling the Relationship Between Exposure to Abiraterone and Prostate-Specific Antigen Dynamics in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Pharmacokinetics, 2017, 56, 55-63.	3.5	16
382	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology, 2017, 71, 656-664.	1.9	67
383	Quality indicators in the management of bladder cancer: A modified Delphi study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 328-334.	1.6	29
384	Population-Based Validation of the 2014 ISUP Gleason Grade Groups in Patients Treated With Radical Prostatectomy, Brachytherapy, External Beam Radiation, or no Local Treatment. Prostate, 2017, 77, 686-693.	2.3	33
385	Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial. Lancet Oncology, The, 2017, 18, 473-485.	10.7	67
386	Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer, 2017, 123, 2303-2311.	4.1	32
387	Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results Database. Urologia Internationalis, 2017, 98, 40-48.	1.3	15
388	External Beam Radiotherapy Affects Serum Testosterone in Patients with Localized Prostate Cancer. Journal of Sexual Medicine, 2017, 14, 876-882.	0.6	16
389	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology, 2017, 72, 10-13.	1.9	32
390	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). Urology, 2017, 104, 150-159.	1.0	29
391	Author Reply. Urology, 2017, 109, 17-18.	1.0	0
392	Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. Lancet Oncology, The, 2017, 18, 1532-1542.	10.7	65
393	The role of bone-targeted therapies for prostate cancer in 2017. Current Opinion in Supportive and Palliative Care, 2017, 11, 216-224.	1.3	4
394	Androgen deprivation in prostate cancer: first do no harm. Lancet Oncology, The, 2017, 18, 1142-1144.	10.7	3
395	Improving cancer care in metastatic kidney and prostate cancer: steps in the right direction. Current Opinion in Supportive and Palliative Care, 2017, 11, 214-215.	1.3	0
396	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. Urology, 2017, 109, 6-18.	1.0	15

#	ARTICLE	IF	CITATIONS
397	Biopsy Based Proteomic Assay Predicts Risk of Biochemical Recurrence after Radical Prostatectomy. Journal of Urology, 2017, 197, 1034-1040.	0.4	10
398	Comorbidity and age cannot explain variation in life expectancy associated with treatment of non-metastatic prostate cancer. World Journal of Urology, 2017, 35, 1031-1036.	2.2	14
399	Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. European Urology, 2017, 71, 151-154.	1.9	306
400	Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 40-47.	1.6	577
401	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population. Clinical Cancer Research, 2017, 23, 1967-1973.	7.0	46
402	Analysis of active surveillance uptake for low-risk localized prostate cancer in Canada: a Canadian multi-institutional study. World Journal of Urology, 2017, 35, 595-603.	2.2	17
403	Screening and treatment: where do we go from here?. Nature Reviews Clinical Oncology, 2017, 14, 7-8.	27.6	1
404	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, 30-7.	0.6	16
405	Canadian Urological Association recommendations on prostate cancer screening and early diagnosis. Canadian Urological Association Journal, 2017, 11, 298-309.	0.6	55
406	Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. Minerva Urology and Nephrology, 2017, 69, 173-180.	2.5	4
407	Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources. BMC Urology, 2017, 17, 98.	1.4	7
408	Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 16.	0.6	20
409	Supplementary data: Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer. Canadian Urological Association Journal, 2017, 11, 62.	0.6	0
410	New research in prostate cancer, ASCO-GU 2017. Canadian Urological Association Journal, 2017, 11, 166.	0.6	2
411	Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial – FIRSTANA. Journal of Clinical Oncology, 2017, 35, 3189-3197.	1.6	251
412	Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naïve, Metastatic, Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3181-3188.	1.6	73
413	Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy. Journal of Clinical Oncology, 2017, 35, 1501-1502.	1.6	0
414	IKK over-expression promotes the growth of prostate cancer through the C/EBP- β dependent activation of IL-6 gene expression. Oncotarget, 2017, 8, 14487-14501.	1.8	16

#	ARTICLE	IF	CITATIONS
415	Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 327-333.	4.9	20
416	Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. Canadian Urological Association Journal, 2016, 10, 82.	0.6	21
417	Addressing concerns around the veracity of scientific research and publication. Canadian Urological Association Journal, 2016, 10, 151.	0.6	0
418	A comparative study of radical prostatectomy and permanent seed brachytherapy for low- and intermediate-risk prostate cancer. Canadian Urological Association Journal, 2016, 10, 246.	0.6	9
419	Suboptimal use of pelvic lymph node dissection: Differences in guideline adherence between robot-assisted and open radical prostatectomy. Canadian Urological Association Journal, 2016, 10, 269.	0.6	7
420	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents. Clinical Cancer Research, 2016, 22, 5713-5721.	7.0	37
421	Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1037-1045.	0.8	21
422	A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks. Biopreservation and Biobanking, 2016, 14, 383-389.	1.0	5
423	Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncology, The, 2016, 17, 1306-1316.	10.7	259
424	Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. Journal of Clinical Oncology, 2016, 34, 3005-3013.	1.6	202
425	The Present and Future of Biomarkers in Prostate Cancer: Proteomics, Genomics, and Immunology Advancements. Biomarkers in Cancer, 2016, 8s2, BIC.S31802.	3.6	70
426	The evolving role of chemotherapy in prostate cancer. Current Opinion in Supportive and Palliative Care, 2016, 10, 262-265.	1.3	1
427	The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. European Urology, 2016, 70, 675-683.	1.9	70
428	Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer. Urology, 2016, 96, 156-164.	1.0	25
429	Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. European Urology, 2016, 70, 429-435.	1.9	16
430	Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies. European Urology, 2016, 69, 924-932.	1.9	22
431	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer. Clinical Cancer Research, 2016, 22, 158-166.	7.0	156
432	Prostatitis, other genitourinary infections and prostate cancer: results from a population-based case-control study. World Journal of Urology, 2016, 34, 425-430.	2.2	17

#	ARTICLE	IF	CITATIONS
433	TAXYNERGY: Randomized trial of early switch from first-line docetaxel (D) to cabazitaxel (C) or vice versa with circulating tumor cell (CTC) biomarkers in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2016, 34, 5007-5007.	1.6	4
434	Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP).. Journal of Clinical Oncology, 2016, 34, 5082-5082.	1.6	20
435	ERA 223: A phase 3 trial of radium-223 dichloride in combination with abiraterone acetate and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant metastatic castration-resistant prostate cancer.. Journal of Clinical Oncology, 2016, 34, TPS5088-TPS5088.	1.6	4
436	Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts).. Journal of Clinical Oncology, 2016, 34, 200-200.	1.6	22
437	Medical management of benign prostatic hyperplasia: Results from a population-based study. Canadian Urological Association Journal, 2016, 10, 55.	0.6	15
438	Enumerating pelvic recurrence following radical cystectomy for bladder cancer: A Canadian multi-institutional study. Canadian Urological Association Journal, 2016, 10, 90.	0.6	6
439	Efficacy, quality of life, and safety of cabazitaxel in Canadian metastatic castration-resistant prostate cancer patients treated or not with prior abiraterone. Canadian Urological Association Journal, 2016, 10, 102.	0.6	12
440	Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015. Canadian Urological Association Journal, 2016, 10, 46.	0.6	55
441	Surrogacy analysis of prostate-specific antigen (PSA) decline for improved overall survival (OS) with enzalutamide (ENZ) in AFFIRM.. Journal of Clinical Oncology, 2016, 34, 266-266.	1.6	0
442	Associate Editor for Review Articles: Dr.ÂFred Saad. Urology, 2015, 86, 209-210.	1.0	0
443	Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4579-4587.	3.6	52
444	Management of bone metastases in prostate cancer. Current Opinion in Supportive and Palliative Care, 2015, 9, 261-267.	1.3	25
445	Metabolic syndrome and prostate cancer risk in a population-based caseâ€control study in Montreal, Canada. BMC Public Health, 2015, 15, 913.	2.9	51
446	Prevalence and risk factors of contralateral extraprostatic extension in men undergoing radical prostatectomy for unilateral disease at biopsy: A global multi-institutional experience. Canadian Urological Association Journal, 2015, 9, 434.	0.6	1
447	Impact of Bone-targeted Therapies in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302. European Urology, 2015, 68, 570-577.	1.9	50
448	Safety of enzalutamide in patients with metastatic castrationâ€resistant prostate cancer previously treated with docetaxel: Expanded access in North America. Prostate, 2015, 75, 836-844.	2.3	17
449	Progress in bladder cancer. Current Opinion in Supportive and Palliative Care, 2015, 9, 244.	1.3	0
450	Development and Clinical Validation of an <i>In Situ</i> Biopsy-Based Multimarker Assay for Risk Stratification in Prostate Cancer. Clinical Cancer Research, 2015, 21, 2591-2600.	7.0	157

#	ARTICLE	IF	CITATIONS
451	Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e123-e130.	1.9	35
452	Burden of Hospital Admissions and Utilization of Hospice Care in Metastatic Prostate Cancer Patients. <i>Urology</i> , 2015, 85, 343-350.	1.0	21
453	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
454	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2015, 16, 152-160.	10.7	1,100
455	The 2014 CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC). <i>Canadian Urological Association Journal</i> , 2015, 9, 90.	0.6	82
456	Androgen Deprivation Therapy in Prostate Cancer: Looking Beyond Prostate-specific Antigen and Testosterone Levels. <i>European Urology</i> , 2015, 67, 837-838.	1.9	4
457	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. <i>Annals of Oncology</i> , 2015, 26, 2044-2056.	1.2	89
458	Androgen-deprivation therapy and bone loss in prostate cancer patients: a clinical review. <i>BoneKEy Reports</i> , 2015, 4, 716.	2.7	35
459	Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. <i>European Urology</i> , 2015, 68, 850-858.	1.9	74
460	Active Surveillance in Prostate Cancer. <i>JAMA Oncology</i> , 2015, 1, 340.	7.1	2
461	BPH: a tell-tale sign of prostate cancer? Results from the Prostate Cancer and Environment Study (PROtEuS). <i>World Journal of Urology</i> , 2015, 33, 2063-2069.	2.2	7
462	Patterns of use and patient characteristics: brachytherapy for localized prostate cancer in octo- and nonagenarians. <i>World Journal of Urology</i> , 2015, 33, 1985-1991.	2.2	3
463	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3170-3177.	7.0	57
464	Current and Emerging Immunotherapies for Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 85, 976-986.	1.0	13
465	Orteronel plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. <i>Lancet Oncology</i> , The, 2015, 16, 338-348.	10.7	106
466	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>European Journal of Cancer</i> , 2015, 51, 1812-1821.	2.8	106
467	The Molecular Taxonomy of Primary Prostate Cancer. <i>Cell</i> , 2015, 163, 1011-1025.	28.9	2,435
468	Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 194-202.	2.0	29

#	ARTICLE	IF	CITATIONS
469	A Practical Approach to the Management of Radiation-Induced Hemorrhagic Cystitis. <i>Drugs</i> , 2015, 75, 1471-1482.	10.9	32
470	Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. <i>Urology</i> , 2015, 86, 852-861.	1.0	42
471	Waist circumference, waist-hip ratio, body mass index, and prostate cancer risk: Results from the North-American case-control study Prostate Cancer & Environment Study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 494.e1-494.e7.	1.6	40
472	The role of clusterin in prostate cancer: treatment resistance and potential as a therapeutic target. <i>Expert Review of Anticancer Therapy</i> , 2015, 15, 1049-1061.	2.4	21
473	Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics. <i>European Urology Focus</i> , 2015, 1, 191-199.	3.1	5
474	Efficacy Outcomes by Baseline Prostate-specific Antigen Quartile in the AFFIRM Trial. <i>European Urology</i> , 2015, 67, 223-230.	1.9	31
475	Final analysis of COMET-1: Cabozantinib (Cabo) versus prednisone (Pred) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) previously treated with docetaxel (D) and abiraterone (A) and/or enzalutamide (E).. <i>Journal of Clinical Oncology</i> , 2015, 33, 139-139.	1.6	25
476	Potential Cross-Talk between Alternative and Classical NF- κ B Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay. <i>PLoS ONE</i> , 2015, 10, e0131024.	2.5	18
477	A retrospective analysis of clinical factors influencing response to treatment with cabazitaxel in patients with metastatic castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 281-281.	1.6	0
478	Bone turnover marker (BTM) levels and clinical outcomes in advanced cancer patients (pts) treated with antiresorptive bone therapies.. <i>Journal of Clinical Oncology</i> , 2015, 33, e22236-e22236.	1.6	0
479	Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2014, 8, 306.	0.6	30
480	The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence. <i>Canadian Urological Association Journal</i> , 2014, 8, 845.	0.6	32
481	Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. <i>Canadian Urological Association Journal</i> , 2014, 8, 195.	0.6	26
482	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014, 32, 3436-3448.	1.6	201
483	Comparison of Fracture Risk Assessment Tool Score to Bone Mineral Density for Estimating Fracture Risk in Patients With Advanced Prostate Cancer on Androgen Deprivation Therapy. <i>Urology</i> , 2014, 84, 164-168.	1.0	19
484	Preventing metastasis to bone: is this the end of the story?. <i>Nature Reviews Urology</i> , 2014, 11, 252-253.	3.8	0
485	Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Na \tilde{A} ve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Pharmacokinetics</i> , 2014, 53, 1149-1160.	3.5	43
486	The RelB alternative NF- κ B subunit promotes autophagy in 22Rv1 prostate cancer cells in vitro and affects mouse xenograft tumor growth in vivo. <i>Cancer Cell International</i> , 2014, 14, 67.	4.1	6

#	ARTICLE	IF	CITATIONS
487	Radiation-induced hemorrhagic cystitis. Current Opinion in Supportive and Palliative Care, 2014, 8, 235-240.	1.3	31
488	Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2014, 20, 1925-1934.	7.0	36
489	Pathologic fracture in patients with metastatic prostate cancer. Current Opinion in Urology, 2014, 24, 595-600.	1.8	8
490	Editorial. Current Opinion in Supportive and Palliative Care, 2014, 8, 234.	1.3	0
491	Prostate-Specific Antigen Kinetics and Outcomes in Patients with Bone Metastases from Castration-Resistant Prostate Cancer Treated with or Without Zoledronic Acid. European Urology, 2014, 65, 146-153.	1.9	13
492	Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 31.e17-31.e24.	1.6	49
493	Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment. European Urology, 2014, 65, 289-299.	1.9	113
494	Toxicities Following Treatment with Bisphosphonates and Receptor Activator of Nuclear Factor- κ B Ligand Inhibitors in Patients with Advanced Prostate Cancer. European Urology, 2014, 65, 278-286.	1.9	41
495	Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer. World Journal of Urology, 2014, 32, 1295-1301.	2.2	13
496	The impact of androgen deprivation therapy (<sc>ADT</sc>) on the risk of cardiovascular (<sc>CV</sc>) events in patients with non-metastatic prostate cancer: a population-based study. BJU International, 2014, 114, E82-E89.	2.5	77
497	Prostate Cancer Genomics as a Driver of Personalized Medicine. , 2014, , 233-245.		1
498	Managing bone metastases and reducing skeletal related events in prostate cancer. Nature Reviews Clinical Oncology, 2014, 11, 335-345.	27.6	110
499	Randomized Controlled Trial of Early Zoledronic Acid in Men With Castration-Sensitive Prostate Cancer and Bone Metastases: Results of CALGB 90202 (Alliance). Journal of Clinical Oncology, 2014, 32, 1143-1150.	1.6	217
500	Role of bisphosphonates in non-metastatic prostate cancer. Lancet Oncology, The, 2014, 15, 1041-1042.	10.7	1
501	Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, The, 2014, 15, e404-e414.	10.7	196
502	Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Lancet Oncology, The, 2014, 15, 1263-1268.	10.7	46
503	Efficacy and Safety of Abiraterone Acetate in an Elderly Patient Subgroup (Aged 75 and Older) with Metastatic Castration-resistant Prostate Cancer After Docetaxel-based Chemotherapy. European Urology, 2014, 65, 875-883.	1.9	74
504	Enzalutamide in Metastatic Prostate Cancer before Chemotherapy. New England Journal of Medicine, 2014, 371, 424-433.	27.0	2,456

#	ARTICLE	IF	CITATIONS
505	The Health Care Burden of Skeletal Related Events in Patients with Renal Cell Carcinoma and Bone Metastasis. Journal of Urology, 2014, 191, 1678-1684.	0.4	19
506	Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302). European Urology, 2014, 66, 815-825.	1.9	221
507	Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: Results from a Canadian multicenter collaboration. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 441-448.	1.6	26
508	Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: Results from the Canadian Upper Tract Collaboration1Co-first authors.. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 839-845.	1.6	44
509	Treatment options in castration-resistant prostate cancer: Current therapies and emerging docetaxel-based regimens. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 70-79.	1.6	30
510	Primary, secondary, and quality-of-life endpoint results from PREVAIL, a phase 3 study of enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2014, 32, 5007-5007.	1.6	4
511	Phase 3, randomized, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients (pts) with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) (ELM-PC 4 trial). Journal of Clinical Oncology, 2014, 32, 5008-5008.	1.6	15
512	Regional differences observed in the phase 3 trial (ELM-PC 5) with orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel.. Journal of Clinical Oncology, 2014, 32, 5042-5042.	1.6	2
513	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2014, 32, 5051-5051.	1.6	2
514	Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).. Journal of Clinical Oncology, 2014, 32, 5062-5062.	1.6	3
515	Distinguishing aggressive versus nonaggressive prostate cancer using a novel prognostic proteomics biopsy test, ProMark.. Journal of Clinical Oncology, 2014, 32, 5090-5090.	1.6	2
516	PROSPER: A phase 3 study of enzalutamide in nonmetastatic (MO) castration-resistant prostate cancer (CRPC) patients.. Journal of Clinical Oncology, 2014, 32, TPS5094-TPS5094.	1.6	5
517	Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).. Journal of Clinical Oncology, 2014, 32, 7-7.	1.6	17
518	Bone-Targeted Therapy: Rationale and Current Status. Current Clinical Urology, 2014, , 139-153.	0.0	0
519	Cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D): Analysis by age group.. Journal of Clinical Oncology, 2014, 32, 109-109.	1.6	0
520	Regional analysis of a cohort compassionate-use program (CUP) and early access program (EAP) with cabazitaxel (Cbz) plus prednisone (P; Cbz + P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel (D).. Journal of Clinical Oncology, 2014, 32, 242-242.	1.6	1
521	Comparison of FRAX score to bone mineral density for estimating fracture risk in patients with CRPC on androgen-deprivation therapy (ADT).. Journal of Clinical Oncology, 2014, 32, 101-101.	1.6	0
522	A randomized, open label, multicenter, phase 3, 2-arm study of androgen deprivation with leuprolide (L), ± docetaxel (D) for clinically asymptomatic prostate cancer (PC) subjects with a rising PSA following definitive local therapy: Safety results.. Journal of Clinical Oncology, 2014, 32, 5022-5022.	1.6	0

#	ARTICLE	IF	CITATIONS
523	The FRAX score as a tool for estimating fracture risk in patients with advanced prostate cancer on androgen-deprivation therapy compared to the conventional T-score.. Journal of Clinical Oncology, 2014, 32, e16023-e16023.	1.6	0
524	The search for alternative androgen-deprivation therapies. Lancet Oncology, The, 2013, 14, 267-268.	10.7	0
525	Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer. European Journal of Cancer, 2013, 49, 2441-2448.	2.8	40
526	Overview of the latest treatments for castration-resistant prostate cancer. Nature Reviews Urology, 2013, 10, 522-528.	3.8	51
527	Denosumab and Bone Metastasis-Free Survival in Men With Nonmetastatic Castration-Resistant Prostate Cancer: Exploratory Analyses by Baseline Prostate-Specific Antigen Doubling Time. Journal of Clinical Oncology, 2013, 31, 3800-3806.	1.6	196
528	Strategies for Biochemical and Pathologic Quality Assurance in a Large Multi-Institutional Biorepository; The Experience of the PROCURE Quebec Prostate Cancer Biobank. Biopreservation and Biobanking, 2013, 11, 285-290.	1.0	17
529	New and Emerging Therapies for Bone Metastases in Genitourinary Cancers. European Urology, 2013, 63, 309-320.	1.9	42
530	Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. New England Journal of Medicine, 2013, 368, 138-148.	27.0	2,412
531	Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial. Lancet Oncology, The, 2013, 14, 1307-1316.	10.7	205
532	Bone-targeted therapy in prostate cancer. European Journal of Cancer, Supplement, 2013, 11, 257-259.	2.2	2
533	Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features-An exploratory analysis of placebo-controlled trials. Journal of Bone Oncology, 2013, 2, 70-76.	2.4	34
534	Comorbidity Status Does Not Independently Predict Survival Outcomes After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma. European Urology, 2013, 64, 518-519.	1.9	2
535	Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1161-1165.	1.6	36
536	Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration. BJU International, 2013, 112, 791-797.	2.5	49
537	Gata3 antagonizes cancer progression in Pten-deficient prostates. Human Molecular Genetics, 2013, 22, 2400-2410.	2.9	37
538	The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Current Opinion in Urology, 2013, 23, 194-200.	1.8	30
539	CUA-CUOG Guidelines for the Management of Castration Resistant Prostate Cancer (CRPC): 2013 Update. Canadian Urological Association Journal, 2013, 7, 231.	0.6	15
540	<i>TMPRSS2-ERG</i> Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair. Clinical Cancer Research, 2013, 19, 5202-5209.	7.0	39

#	ARTICLE	IF	CITATIONS
541	Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal health care system. Canadian Urological Association Journal, 2013, 7, 667.	0.6	6
542	Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen. Cancer Medicine, 2013, 2, 468-477.	2.8	18
543	Evidence for the efficacy of enzalutamide in postchemotherapy metastatic castrate-resistant prostate cancer. Therapeutic Advances in Urology, 2013, 5, 201-210.	2.0	38
544	Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes and Development, 2013, 27, 900-915.	5.9	158
545	The importance of quality indicators: a call to action. Canadian Urological Association Journal, 2013, 3, 435.	0.6	2
546	Should urologists give chemotherapy?. Canadian Urological Association Journal, 2013, 2, 135.	0.6	1
547	Bone health in the prostate cancer patient receiving androgen deprivation therapy: a review of present and future management options. Canadian Urological Association Journal, 2013, 4, 129.	0.6	14
548	Interim safety analysis of a compassionate-use program (CUP) and early-access program (EAP) providing cabazitaxel (Cbz) plus prednisone (P) to patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. Journal of Clinical Oncology, 2013, 31, 5055-5055.	1.6	1
549	Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.. Journal of Clinical Oncology, 2013, 31, 5079-5079.	1.6	2
550	Hypocalcemia in patients with metastatic bone disease receiving denosumab.. Journal of Clinical Oncology, 2013, 31, 9628-9628.	1.6	2
551	Incidence of osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases from solid tumors or multiple myeloma: Results from three phase III trials.. Journal of Clinical Oncology, 2013, 31, 9640-9640.	1.6	4
552	Cabazitaxel in docetaxel-pretreated metastatic castration resistant prostate cancer (mCRPC): Canadian experience.. Journal of Clinical Oncology, 2013, 31, e16082-e16082.	1.6	1
553	Impact of on-study corticosteroid use on efficacy and safety in the phase III AFFIRM study of enzalutamide (ENZA), an androgen receptor inhibitor.. Journal of Clinical Oncology, 2013, 31, 6-6.	1.6	36
554	Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology, 2013, 31, LBA8-LBA8.	1.6	30
555	Bone Health: Prevention of Skeletal-Related Events and Palliative Care. , 2013, , 935-940.		0
556	Chemotherapy for prostate cancer: Clinical practice in Canada. Canadian Urological Association Journal, 2013, 7, S5-S10.	0.6	4
557	Metastatic castration-resistant prostate cancer: The emerging continuum of care. Canadian Urological Association Journal, 2013, 7, S3.	0.6	1
558	Quality of life (QoL) of patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel.. Journal of Clinical Oncology, 2013, 31, e16088-e16088.	1.6	0

#	ARTICLE	IF	CITATIONS
559	Psychosocial Adjustment of Men During the First Year of Prostate Cancer. <i>Cancer Nursing</i> , 2012, 35, 141-147.	1.5	18
560	PTP1B Is an Androgen Receptor-Regulated Phosphatase That Promotes the Progression of Prostate Cancer. <i>Cancer Research</i> , 2012, 72, 1529-1537.	0.9	74
561	Preventing bone complications in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 299-303.	1.3	5
562	Sarcopenia During Androgen-Deprivation Therapy for Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 3271-3276.	1.6	148
563	Bisphosphonate Anticancer Activity in Prostate Cancer and Other Genitourinary Cancers. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2012, 12, 129-136.	1.7	5
564	p53 Inhibits Angiogenesis by Inducing the Production of Arresten. <i>Cancer Research</i> , 2012, 72, 1270-1279.	0.9	58
565	Bone-modifying agents in the treatment of bone metastases in patients with advanced genitourinary malignancies: a focus on zoledronic acid. <i>Therapeutic Advances in Urology</i> , 2012, 4, 85-101.	2.0	14
566	Intermittent Androgen Suppression for Rising PSA Level after Radiotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 895-903.	27.0	428
567	The current role of circulating tumor cells in the diagnosis and management of bone metastases in advanced prostate cancer. <i>Future Oncology</i> , 2012, 8, 321-331.	2.4	40
568	Prognostic Role of Serum Parathyroid Hormone Levels in Advanced Prostate Cancer Patients Undergoing Zoledronic Acid Administration. <i>Oncologist</i> , 2012, 17, 645-652.	3.7	23
569	Bisphosphonates: Prevention of Bone Metastases in Prostate Cancer. <i>Recent Results in Cancer Research</i> , 2012, 192, 109-126.	1.8	10
570	Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. <i>Lancet</i> , The, 2012, 379, 39-46.	13.7	716
571	Denosumab in castration-resistant prostate cancer – Authors' reply. <i>Lancet</i> , The, 2012, 379, e50-e51.	13.7	0
572	Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. <i>New England Journal of Medicine</i> , 2012, 367, 1187-1197.	27.0	3,847
573	Prostate cancer therapy: finding the right balance. <i>Lancet Oncology</i> , The, 2012, 13, 119-120.	10.7	1
574	Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy. <i>Cell and Tissue Banking</i> , 2012, 13, 631-638.	1.1	14
575	Re: Combined Androgen Deprivation Therapy and Radiation Therapy for Locally Advanced Prostate Cancer: A Randomised, Phase 3 Trial. <i>European Urology</i> , 2012, 62, 932-933.	1.9	0
576	Biochemical markers of bone turnover and clinical outcomes in men with prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 369-378.	1.6	28

#	ARTICLE	IF	CITATIONS
577	Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. <i>Annals of Oncology</i> , 2012, 23, 1341-1347.	1.2	613
578	The Contemporary Role of Lymph Node Dissection During Nephroureterectomy in the Management of Upper Urinary Tract Urothelial Carcinoma: The Canadian Experience. <i>Urology</i> , 2012, 79, 840-845.	1.0	53
579	Integrative Molecular Profiling Reveals Asparagine Synthetase Is a Target in Castration-Resistant Prostate Cancer. <i>American Journal of Pathology</i> , 2012, 180, 895-903.	3.8	72
580	Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. <i>European Journal of Cancer</i> , 2012, 48, 3082-3092.	2.8	485
581	Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology</i> , The, 2012, 13, 983-992.	10.7	1,182
582	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. <i>American Journal of Pathology</i> , 2012, 181, 401-412.	3.8	278
583	Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. <i>Canadian Urological Association Journal</i> , 2012, 6, 465.	0.6	44
584	ErbB2/Herâ€2 regulates the expression of Akt2 in prostate cancer cells. <i>Prostate</i> , 2012, 72, 777-788.	2.3	6
585	Could targeting bone delay cancer progression? Potential mechanisms of action of bisphosphonates. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 82, 233-248.	4.4	12
586	Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. <i>BJU International</i> , 2012, 110, 1317-1323.	2.5	50
587	Primary, secondary, and quality-of-life endpoint results from the phase III AFFIRM study of MDV3100, an androgen receptor signaling inhibitor.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4519-4519.	1.6	22
588	Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study.. <i>Journal of Clinical Oncology</i> , 2012, 30, LBA1-LBA1.	1.6	66
589	Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. <i>Canadian Urological Association Journal</i> , 2012, 6, 465-70.	0.6	43
590	Health resource utilization and patient burden associated with SREs in a randomized controlled trial setting.. <i>Journal of Clinical Oncology</i> , 2012, 30, e19514-e19514.	1.6	0
591	Effect of denosumab on prolonging bone-metastasis free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4510-4510.	1.6	7
592	NF-ÎB p65 as a prognostic tool in prostate cancer: An immunohistochemical study from biopsy samples.. <i>Journal of Clinical Oncology</i> , 2012, 30, e15202-e15202.	1.6	0
593	Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada. <i>Canadian Urological Association Journal</i> , 2012, 6, 455-62.	0.6	7
594	717 EVALUATION OF PROSTATE-SPECIFIC ANTIGEN KINETICS DURING ZOLEDRONIC ACID THERAPY FOR BONE METASTASES IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER. <i>Journal of Urology</i> , 2011, 185, .	0.4	3

#	ARTICLE	IF	CITATIONS
595	Abiraterone and Increased Survival in Metastatic Prostate Cancer. New England Journal of Medicine, 2011, 364, 1995-2005.	27.0	3,736
596	ES25 Management of castration resistant prostate cancer. Japanese Journal of Urology, 2011, 102, 78.	0.1	0
597	Bone health in prostate cancer. Expert Review of Endocrinology and Metabolism, 2011, 6, 317-321.	2.4	1
598	Influence of pH on the cytotoxic activity of inositol hexakisphosphate (IP6) in prostate cancer. Frontiers in Oncology, 2011, 1, 40.	2.8	1
599	Searching for bone metastases—how, when and why?. Nature Reviews Urology, 2011, 8, 358-359.	3.8	0
600	Consensus on the utility of bone markers in the malignant bone disease setting. Critical Reviews in Oncology/Hematology, 2011, 80, 411-432.	4.4	84
601	New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety. European Urology, 2011, 60, 279-290.	1.9	130
602	Androgen Deprivation and Bone. Current Osteoporosis Reports, 2011, 9, 20-24.	3.6	1
603	I κ B α Kinase β (IKK β /IKKi/I κ BK β) expression and localization in prostate cancer tissues. Prostate, 2011, 71, 1131-1138.	1.3	18
604	Macropinocytosis inhibitors and Arf6 regulate ErbB3 nuclear localization in prostate cancer cells. Molecular Carcinogenesis, 2011, 50, 901-912.	2.7	22
605	Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. Journal of Bone and Mineral Research, 2011, 26, 2827-2833.	2.8	28
606	Penile cancer. Current Opinion in Supportive and Palliative Care, 2011, 5, 185-191.	1.3	13
607	Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c. Clinical Cancer Research, 2011, 17, 5765-5773.	7.0	120
608	Regulation of E2Fs and senescence by PML nuclear bodies. Genes and Development, 2011, 25, 41-50.	5.9	132
609	Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group. Canadian Urological Association Journal, 2011, 5, 379-381.	0.6	0
610	Bone complications of androgen deprivation therapy: screening, prevention, and treatment. Current Opinion in Urology, 2010, 20, 247-252.	1.8	16
611	Phenotypic characterization of chronic inflammation in a rare case of endobronchial carcinoma. Cancer Immunology, Immunotherapy, 2010, 59, 1411-1416.	4.2	0
612	The Rate of Secondary Malignancies After Radical Prostatectomy Versus External Beam Radiation Therapy for Localized Prostate Cancer: A Population-Based Study on 17,845 Patients. International Journal of Radiation Oncology Biology Physics, 2010, 76, 342-348.	0.8	93

#	ARTICLE	IF	CITATIONS
613	Zoledronic Acid Use in Patients With Bone Metastases From Renal Cell Carcinoma or Bladder Cancer. <i>Seminars in Oncology</i> , 2010, 37, S38-S44.	2.2	21
614	Maintaining Bone Health in Prostate Cancer Throughout the Disease Continuum. <i>Seminars in Oncology</i> , 2010, 37, S30-S37.	2.2	5
615	Background for the proposal of SIOG guidelines for the management of prostate cancer in senior adults. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 73, 68-91.	4.4	105
616	A novel method of cell embedding for tissue microarrays. <i>Histopathology</i> , 2010, 57, 323-329.	2.9	6
617	Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. <i>BJU International</i> , 2010, 106, 462-469.	2.5	207
618	PROSTATE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY: SOONER OR LATER?. <i>BJU International</i> , 2010, 106, 946-948.	2.5	1
619	Bone-marker levels in patients with prostate cancer: potential correlations with outcomes. <i>Current Opinion in Supportive and Palliative Care</i> , 2010, 4, 127-134.	1.3	15
620	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 14134-14139.	7.1	447
621	Optimizing Clinical Benefits of Bisphosphonates in Cancer Patients with Bone Metastases. <i>Oncologist</i> , 2010, 15, 1147-1158.	3.7	42
622	Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 4247-4254.	1.6	221
623	SRC kinase inhibition: Targeting bone metastases and tumor growth in prostate and breast cancer. <i>Cancer Treatment Reviews</i> , 2010, 36, 177-184.	7.7	109
624	Identification of Spermatozoa in Archived Testicular Cancer Specimens: Implications for Bench Side Sperm Retrieval at Orchiectomy. <i>Urology</i> , 2010, 75, 1436-1440.	1.0	16
625	Zoledronic Acid Improves Clinical Outcomes When Administered Before Onset of Bone Pain in Patients With Prostate Cancer. <i>Urology</i> , 2010, 76, 1175-1181.	1.0	67
626	Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1991-2002.	2.4	8
627	Disease Progression Increases the Risk of Skeletal-Related Events in Patients With Bone Metastases From Castration-Resistant Prostate Cancer, Lung Cancer, or Other Solid Tumors. <i>Cancer Investigation</i> , 2010, 28, 849-855.	1.3	23
628	Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer. <i>PLoS ONE</i> , 2010, 5, e12107.	2.5	45
629	The aging male population and medical care for benign prostatic hyperplasia in Canada. <i>Canadian Urological Association Journal</i> , 2010, 4, 123-127.	0.6	13
630	Guidelines for the management of castrate-resistant prostate cancer. <i>Canadian Urological Association Journal</i> , 2010, 4, 380-384.	0.6	120

#	ARTICLE	IF	CITATIONS
631	Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine, 2009, 361, 745-755.	27.0	1,010
632	A Simple and Accurate Model for Prediction of Cancer-Specific Mortality in Patients Treated with Surgery for Primary Penile Squamous Cell Carcinoma. Clinical Cancer Research, 2009, 15, 1013-1018.	7.0	34
633	Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. Journal of Immunological Methods, 2009, 348, 9-17.	1.4	219
634	Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets. European Urology, 2009, 56, 594-605.	1.9	174
635	Overexpression of Î²Bâ€kinaseâ€µ (IKKÎµ/IKKi) induces secretion of inflammatory cytokines in prostate cancer cell lines. Prostate, 2009, 69, 706-718.	2.3	34
636	Src as a therapeutic target in men with prostate cancer and bone metastases. BJU International, 2009, 103, 434-440.	2.5	54
637	Preserving bone health in patients with hormoneâ€sensitive prostate cancer: the role of bisphosphonates. BJU International, 2009, 104, 1573-1579.	2.5	23
638	Population-based Analysis of Normal Total PSA and Percentage of Free/Total PSA Values: Results From Screening Cohort. Urology, 2009, 73, 1323-1327.	1.0	12
639	Population-based Study of Perioperative Mortality After Retroperitoneal Lymphadenectomy for Nonseminomatous Testicular Germ Cell Tumors. Urology, 2009, 74, 373-377.	1.0	47
640	Partial Cystectomy Does Not Undermine Cancer Control in Appropriately Selected Patients With Urothelial Carcinoma of the Bladder: A Population-based Matched Analysis. Urology, 2009, 74, 858-864.	1.0	77
641	New opportunities in the management of prostate cancerâ€related bone complications. Urologic Oncology: Seminars and Original Investigations, 2009, 27, S1-S20.	1.6	6
642	Treatment Decisions for Advanced Genitourinary Cancers: From Symptoms to Risk Assessment. European Urology Supplements, 2009, 8, 738-746.	0.1	5
643	Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum. European Urology Supplements, 2009, 8, 733-737.	0.1	2
644	RANK Ligand Inhibition: A Novel Strategy for the Treatment of Bone Metastases. European Urology Supplements, 2009, 8, 829-833.	0.1	1
645	Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology, 2009, 182, 2670-2676.	0.4	93
646	Nomogram Predicting the Probability of Early Recurrence After Radical Prostatectomy for Prostate Cancer. Journal of Urology, 2009, 181, 601-608.	0.4	129
647	Predicting life expectancy in prostate cancer patients. Current Opinion in Supportive and Palliative Care, 2009, 3, 166-169.	1.3	23
648	The current management of small renal masses. Current Opinion in Supportive and Palliative Care, 2009, 3, 180-185.	1.3	4

#	ARTICLE	IF	CITATIONS
649	Biphosphonates In The Management Of Metastatic Bone Disease. Cancer Metastasis - Biology and Treatment, 2009, , 195-231.	0.1	1
650	Survival after radical prostatectomy and radiotherapy for prostate cancer: a population-based study. Canadian Urological Association Journal, 2009, 3, 13-21.	0.6	17
651	Ebp1 expression in benign and malignant prostate. Cancer Cell International, 2008, 8, 18.	4.1	13
652	Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer, 2008, 113, 193-201.	4.1	243
653	Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormoneâ€refractory prostate cancer. Cancer, 2008, 113, 2478-2487.	4.1	230
654	Mortality at 120 days after prostatic biopsy: A populationâ€based study of 22,175 men. International Journal of Cancer, 2008, 123, 647-652.	5.1	44
655	Targeting the receptor activator of nuclear factorâ€B (RANK) ligand in prostate cancer bone metastases. BJU International, 2008, 101, 1071-1075.	2.5	26
656	Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis. BJU International, 2008, 101, 1302-1309.	2.5	22
657	Accuracy of life tables in predicting overall survival in patients after radical prostatectomy. BJU International, 2008, 102, 33-38.	2.5	25
658	RESEARCH IN GENITOURINARY ONCOLOGY: THE CANADIAN URO-ONCOLOGY GROUP MULTIDISCIPLINARY MODEL. BJU International, 2008, 102, 7-8.	2.5	1
659	The Canadian Uroâ€Oncology Group multicentre phase II study of docetaxel administered every 3â€weeks with prednisone in men with metastatic hormoneâ€refractory prostate cancer progressing after mitoxantrone/prednisone. BJU International, 2008, 102, 551-555.	2.5	12
660	Poor Overall Survival in Septa- and Octogenarian Patients after Radical Prostatectomy and Radiotherapy for Prostate Cancer: A Population-Based Study of 6183 Men. European Urology, 2008, 54, 107-117.	1.9	32
661	High Provider Volume is Associated with Lower Rate of Secondary Therapies after Definitive Radiotherapy for Localized Prostate Cancer. European Urology, 2008, 54, 97-106.	1.9	17
662	New research findings on zoledronic acid: Survival, pain, and anti-tumour effects. Cancer Treatment Reviews, 2008, 34, 183-192.	7.7	61
663	OC4. Number and sites of bone lesions and history of skeletal-related events (SREs): Do these parameters correspond with skeletal morbidity and mortality in patients with bone metastases (mets) from hormone-refractory prostate cancer (HRPC)?. Cancer Treatment Reviews, 2008, 34, 50-51.	7.7	0
664	P81. Meta-analysis of effects of zoledronic acid (ZOL) on survival in patients with metastatic bone disease (MBD) and high bone turnover. Cancer Treatment Reviews, 2008, 34, 43.	7.7	4
665	Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based Biomarkers. Clinical Cancer Research, 2008, 14, 3785-3791.	7.0	79
666	Cancer Treatmentâ€Induced Bone Loss in Breast and Prostate Cancer. Journal of Clinical Oncology, 2008, 26, 5465-5476.	1.6	164

#	ARTICLE	IF	CITATIONS
667	Advancing Treatment for Metastatic Bone Cancer: Consensus Recommendations from the Second Cambridge Conference. <i>Clinical Cancer Research</i> , 2008, 14, 6387-6395.	7.0	64
668	Factors influencing treatment decisions in patients with low risk prostate cancer referred to a brachytherapy clinic. <i>Canadian Journal of Urology</i> , 2008, 15, 4415-20.	0.0	8
669	Regulation of I κ B Kinase μ Expression by the Androgen Receptor and the Nuclear Factor- κ B Transcription Factor in Prostate Cancer. <i>Molecular Cancer Research</i> , 2007, 5, 87-94.	3.4	23
670	Should patients with prostate cancer without bone metastases receive sodium clodronate?. <i>Nature Reviews Urology</i> , 2007, 4, 584-585.	1.4	2
671	Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. <i>Nature Reviews Urology</i> , 2007, 4, S3-S13.	1.4	10
672	NOXA and PUMA Expression Add to Clinical Markers in Predicting Biochemical Recurrence of Prostate Cancer Patients in a Survival Tree Model. <i>Clinical Cancer Research</i> , 2007, 13, 7044-7052.	7.0	32
673	Introduction: A multidisciplinary approach to genitourinary malignancy: does this topic warrant further debate?. <i>Nature Reviews Urology</i> , 2007, 4, S1-S2.	1.4	0
674	Preservation of bone health in prostate cancer. <i>Current Opinion in Supportive and Palliative Care</i> , 2007, 1, 192-197.	1.3	8
675	Predictors of Skeletal Complications in Men with Hormone-Refractory Metastatic Prostate Cancer. <i>Urology</i> , 2007, 70, 315-319.	1.0	62
676	Bisphosphonates Can Prevent Skeletal Complications of Malignant Bone Disease from Prostate Cancer and Renal Cell Carcinoma. <i>European Urology Supplements</i> , 2007, 6, 683-688.	0.1	11
677	Continuing Benefit of Zoledronic Acid in Preventing Skeletal Complications in Patients with Bone Metastases. <i>Clinical Genitourinary Cancer</i> , 2007, 5, 390-396.	1.9	45
678	Pathologic fractures correlate with reduced survival in patients with malignant bone disease. <i>Cancer</i> , 2007, 110, 1860-1867.	4.1	559
679	A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormoneâ€‘refractory prostate cancer. <i>Cancer</i> , 2007, 110, 1959-1966.	4.1	276
680	Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. <i>BJU International</i> , 2007, 100, 37-41.	2.5	19
681	Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer. <i>BJU International</i> , 2007, 100, 303-309.	2.5	31
682	Clinicians are poor raters of lifeâ€‘expectancy before radical prostatectomy or definitive radiotherapy for localized prostate cancer. <i>BJU International</i> , 2007, 100, 1254-1258.	2.5	129
683	Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. <i>BJU International</i> , 2007, 100, 1249-1253.	2.5	16
684	NF- κ B2 processing and p52 nuclear accumulation after androgenic stimulation of LNCaP prostate cancer cells. <i>Cellular Signalling</i> , 2007, 19, 1093-1100.	3.6	27

#	ARTICLE	IF	CITATIONS
685	Sunitinib Relieves Renal Cell Carcinoma Spinal Cord Compression. <i>European Urology</i> , 2007, 51, 1741-1743.	1.9	10
686	Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. <i>European Urology</i> , 2007, 52, 1374-1380.	1.9	16
687	Prostate-Specific Antigen Improves the Ability of Clinical Stage and Biopsy Gleason Sum to Predict the Pathologic Stage at Radical Prostatectomy in the New Millennium. <i>European Urology</i> , 2007, 52, 1067-1075.	1.9	19
688	Clinical Benefits and Considerations of Bisphosphonate Treatment in Metastatic Bone Disease. <i>Seminars in Oncology</i> , 2007, 34, S17-S23.	2.2	41
689	Effects of skeletal morbidities on longitudinal patient-reported outcomes and survival in patients with metastatic prostate cancer. <i>Supportive Care in Cancer</i> , 2007, 15, 869-876.	2.2	130
690	PCPT, MTOPS and the use of 5ARIs: a Canadian consensus regarding implications for clinical practice. <i>Canadian Urological Association Journal</i> , 2007, 1, 17-21.	0.6	12
691	Isolated solitary bony metastasis of a nonseminomatous germ cell tumor. <i>Canadian Journal of Urology</i> , 2007, 14, 3458-60.	0.0	5
692	Optimizing patient therapy: the role of bone markers?. <i>Cancer Treatment Reviews</i> , 2006, 32, 3-6.	7.7	4
693	The Treatment Continuum in the Management of Prostate Cancer Patients: What's New?. <i>European Urology Supplements</i> , 2006, 5, 539-542.	0.1	4
694	Impact of Bone Metastases on Patient's Quality of Life and Importance of Treatment. <i>European Urology Supplements</i> , 2006, 5, 547-550.	0.1	5
695	Bone-Directed Treatments for Prostate Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2006, 20, 947-963.	2.2	16
696	The Role of Bisphosphonates in the Treatment of Prostate Cancer: Recommendations from an Expert Panel. <i>Clinical Genitourinary Cancer</i> , 2006, 4, 257-262.	1.9	34
697	Rationale for zoledronic acid therapy in men with hormone-sensitive prostate cancer with or without bone metastasis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2006, 24, 4-12.	1.6	40
698	An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell lines. <i>Prostate</i> , 2006, 66, 1245-1256.	2.3	17
699	Presence of prostate cancer metastasis correlates with lower lymph node reactivity. <i>Prostate</i> , 2006, 66, 1710-1720.	2.3	28
700	ZOLEDRONIC ACID IS EFFECTIVE IN PREVENTING AND DELAYING SKELETAL EVENTS IN PATIENTS WITH BONE METASTASES SECONDARY TO GENITOURINARY CANCERS. <i>BJU International</i> , 2006, 97, 1351-1352.	2.5	17
701	The role of bisphosphonates in the management of prostate cancer. <i>Current Oncology Reports</i> , 2006, 8, 221-227.	4.0	10
702	Adaptation of wives to prostate cancer following diagnosis and 3 months after treatment: A test of family adaptation theory. <i>International Journal of Nursing Studies</i> , 2006, 43, 827-838.	5.6	27

#	ARTICLE	IF	CITATIONS
703	Natural History and Treatment of Bone Complications in Prostate Cancer. European Urology, 2006, 49, 429-440.	1.9	78
704	High Radical Prostatectomy Surgical Volume is Related to Lower Radical Prostatectomy Total Hospital Charges. European Urology, 2006, 50, 58-63.	1.9	23
705	Nuclear Localization of Nuclear Factor- κ B p65 in Primary Prostate Tumors Is Highly Predictive of Pelvic Lymph Node Metastases. Clinical Cancer Research, 2006, 12, 5741-5745.	7.0	75
706	Isolation of Human Prostatic Epithelial Plasma Membranes for Proteomics Using Mirror Image Tissue Banking of Radical Prostatectomy Specimens. Clinical Cancer Research, 2006, 12, 4178-4184.	7.0	12
707	Markers of Bone Metabolism and Survival in Men with Hormone-Refractory Metastatic Prostate Cancer. Clinical Cancer Research, 2006, 12, 3361-3367.	7.0	156
708	Expression and Nuclear Localization of ErbB3 in Prostate Cancer. Clinical Cancer Research, 2006, 12, 2730-2737.	7.0	114
709	Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU International, 2005, 96, 964-969.	2.5	57
710	The role of bisphosphonates in hormone-refractory prostate cancer. World Journal of Urology, 2005, 23, 14-18.	2.2	25
711	EGFR and Her-2 regulate the constitutive activation of NF-kappaB in PC-3 prostate cancer cells. Prostate, 2005, 65, 130-140.	2.3	61
712	Independent role of phosphoinositol-3-kinase (PI3K) and casein kinase II (CK-2) in EGFR and Her-2-mediated constitutive NF-kappaB activation in prostate cancer cells. Prostate, 2005, 65, 306-315.	2.3	30
713	Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid. Journal of Clinical Oncology, 2005, 23, 4925-4935.	1.6	493
714	Natural History of Rising Serum Prostate-Specific Antigen in Men With Castrate Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 2005, 23, 2918-2925.	1.6	430
715	Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute, 2005, 97, 59-69.	6.3	522
716	Clinical Benefit of Zoledronic Acid for the Prevention of Skeletal Complications in Advanced Prostate Cancer. Clinical Prostate Cancer, 2005, 4, 31-37.	2.1	54
717	Zoledronic acid: past, present and future roles in cancer treatment. Future Oncology, 2005, 1, 149-159.	2.4	15
718	Prognostic Significance of Biochemical Markers of Bone Metabolism in Patients with Bone Lesions from Multiple Myeloma (MM).. Blood, 2005, 106, 5015-5015.	1.4	0
719	Exploration of health-related quality of life areas that may distinguish between continent diversion and ileal conduit patients. Canadian Journal of Urology, 2005, 12, 2537-42.	0.0	4
720	Bone loss in prostate cancer: evaluation, treatment and prevention. Canadian Journal of Urology, 2005, 12 Suppl 1, 71-6; discussion 99-100.	0.0	1

#	ARTICLE	IF	CITATIONS
721	Validation of 1997 Partin Tables' lymph node invasion predictions in men treated with radical prostatectomy in Montreal Quebec. Canadian Journal of Urology, 2005, 12, 2588-92.	0.0	13
722	Canadian guidelines for the management of benign prostatic hyperplasia. Canadian Journal of Urology, 2005, 12, 2677-83.	0.0	21
723	Early symptom improvement of benign prostatic hyperplasia (BPH) treated with once daily alfuzosin. Canadian Journal of Urology, 2005, 12, 2745-54.	0.0	2
724	Validation of prostate cancer index and SF-12 short forms. Canadian Journal of Urology, 2005, 12, 2873-9.	0.0	12
725	An epidural abscess following transrectal ultrasound-guided biopsies of the prostate. Canadian Journal of Urology, 2005, 12, 2899-900.	0.0	9
726	Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer. Journal of the National Cancer Institute, 2004, 96, 879-882.	6.3	1,081
727	Nuclear Factor- κ B Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate Cancer. Clinical Cancer Research, 2004, 10, 8460-8464.	7.0	130
728	RESPONSE: Re: Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate Cancer. Journal of the National Cancer Institute, 2004, 96, 1480-1481.	6.3	5
729	Role of Bisphosphonates in Prostate Cancer. European Urology, 2004, 45, 26-34.	1.9	60
730	Skeletal Morbidity in Men with Prostate Cancer: Quality-of-Life Considerations throughout the Continuum of Care. European Urology, 2004, 46, 731-740.	1.9	62
731	Expression of NF- κ B in prostate cancer lymph node metastases. Prostate, 2004, 58, 308-313.	2.3	88
732	COST-EFFECTIVENESS OF ZOLEDRONIC ACID FOR THE PREVENTION OF SKELETAL COMPLICATIONS IN PATIENTS WITH PROSTATE CANCER. Journal of Urology, 2004, 171, 1537-1542.	0.4	58
733	uPM3, a new molecular urine test for the detection of prostate cancer. Urology, 2004, 64, 311-315.	1.0	160
734	Preventing Bone Complications in Patients with Prostate Cancer: The Emerging Role of Zoledronic Acid. European Urology Supplements, 2004, 3, 25-33.	0.1	6
735	The American Urological Association 2003 guideline on management of benign prostatic hyperplasia: a Canadian opinion. Canadian Journal of Urology, 2004, 11, 2186-93.	0.0	14
736	A prospective randomized trial of 1-day versus 3-day antibiotic prophylaxis for transrectal ultrasound guided prostate biopsy. Canadian Journal of Urology, 2004, 11, 2216-9.	0.0	73
737	Recurrence of a non-seminomatous germ cell tumor in the seminal vesicle 20 years after initial diagnosis and treatment. Canadian Journal of Urology, 2004, 11, 2350-1.	0.0	2
738	The role of bisphosphonates in the management of bone metastases in prostate cancer. Canadian Journal of Urology, 2004, 11, 2376-82.	0.0	9

#	ARTICLE	IF	CITATIONS
739	Digital Rectal Exam Following Prostatectomy: Is It Still Necessary with the Use of PSA?. European Urology, 2003, 43, 333-336.	1.9	21
740	Bisphosphonates in Prostate Cancer: Where Are We and Where Should We Go?. Journal of the National Cancer Institute, 2003, 95, 1262-1263.	6.3	2
741	The New Bisphosphonate, Zometa [®] (Zoledronic Acid), Decreases Skeletal Complications in Both Osteolytic and Osteoblastic Lesions: A Comparison to Pamidronate. Cancer Investigation, 2002, 20, 45-54.	1.3	170
742	A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma. Journal of the National Cancer Institute, 2002, 94, 1458-1468.	6.3	1,557
743	Zoledronic Acid Significantly Reduces Pathologic Fractures in Patients with Advanced-Stage Prostate Cancer Metastatic to Bone. Clinical Prostate Cancer, 2002, 1, 145-152.	2.1	46
744	Gleason score on biopsy: is it reliable for predicting the final grade on pathology?. BJU International, 2002, 90, 694-698.	2.5	85
745	Treatment of bone complications in advanced prostate cancer: Rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Seminars in Oncology, 2002, 29, 19-27.	2.2	71
746	A prospective randomized trial comparing lidocaine and lubricating gel on pain level in patients undergoing transrectal ultrasound prostate biopsy. Canadian Journal of Urology, 2002, 9, 1592-4.	0.0	21
747	Patient-reported outcomes following radical prostatectomy. Canadian Journal of Urology, 1999, 6, 705.	0.0	1
748	Absence of human papillomavirus sequences in early stage prostate cancer. Canadian Journal of Urology, 1999, 6, 834-838.	0.0	13
749	Interferon Gamma-1b Compared with Placebo in Metastatic Renal-Cell Carcinoma. New England Journal of Medicine, 1998, 338, 1265-1271.	27.0	289
750	Overexpression of her-2/neu in human prostate cancer and benign hyperplasia. Cancer Letters, 1996, 99, 185-189.	7.2	56
751	Staghorn calculi treated by percutaneous nephrolithotomy: risk factors for recurrence. Urology, 1993, 41, 141-143.	1.0	11
752	Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer and Prostatic Diseases, 0, , .	3.9	4